The Pharmaceutical Market: Denmark
OVERVIEW OF THE PHARMACEUTICAL
MARKET IN DENMARK
The macroenvironment for the Danish
pharmaceutical industry is improving. The centre-left coalition, of
the Social Democratic Party, the Socialist People\'s Party and the
Social Liberal Party, took office in October 2011. Denmark suffered a
deep recession and economic recovery is stalling with negative GDP
growth projected for 2012. Denmark has an ageing population, and the
Economist Intelligence Unit projects that the population aged 65 and
over will constitute more than one-fifth of the total population by
2016. As a result, healthcare is increasingly focused on preventative
care and there will be a continuing demand for new therapies so that
patients can be treated more effectively.
The increasing pharmaceutical expenditure
in Denmark has led to price freezes and caps in recent years. A price
ceiling, which has fixed pharmaceutical prices at the level they were
five years ago, was extended to remain in place until the end of
2011. This extension is a sign of the government’s determination to
keep the price of pharmaceuticals down, and so this form of price
restriction is likely to continue beyond 2011. However, despite the
positive results from cost-containment measures, efforts to reduce
the cost of pharmaceuticals have proved unsuccessful. The savings
made have been more than counterbalanced by the wider use of new and
expensive pharmaceuticals, which are required to ensure the most
effective treatment. This is especially true in areas such as
hypertension, high cholesterol and so on, where many new therapies
have become available recently.
To
Browse a Full Report with TOC @
http://www.researchmoz.us/the-pharmaceutical-market-denmark-report.html
Denmark
has strong domestic production, but many producers focus on the
export market. Due to the presence of Novo Nordisk, Denmark is a
major global supplier of insulin in retail form. In August 2011, Novo
Nordisk announced it is planning to build two new office buildings in
Bagsværd. Previously, in June 2011, the company announced it is to
invest in a new plant in Kalundborg, for the production of
biopharmaceuticals.
Competitive
Landscape
The
competitive landscape section provides comparative company analyses
and rankings by US$ sales and % share of total sales - for the total
pharmaceutical sector, as well as the OTC, generics, and distribution
sub-sectors.
Table
of Contents
Ambulatory
Care 31
Services
31
Table:
Hospital Activity, 2005-2009 31
Table:
Hospital Activity in Short-Stay Units, 2009 32
Table:
Diagnostic & Therapeutic Procedures Performed in Public &
Private Hospitals, 2009 33
Ambulatory
Activity 34
Table:
Regional Ranking Of Projected Physicians, 2017 34
Table:
Projected Physicians, 2012-2017 35
Latest
Figures 35
Table:
Medical Personnel, 2005-2010 35
Encouragement
Of Generic Drug Use 36
Research
And Development 37
For More Information Kindly Contact:
ResearchMoz
Mr.
Nachiket Ghumare,
Tel:
866-997-4948
(Us-Canada
Toll Free)
Tel:
+1-518-621-2074
Website:
http://www.researchmoz.us
Comments
Post a Comment